SABS – sab biotherapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

SABS

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/11

02:39 pm

sabs

Rating for SABS

Low Report

Rating for SABS

Report

1/9

06:10 am

sabs

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.

Low Report

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.

Report

1/7

03:27 pm

sabs

Rating for SABS

Low Report

Rating for SABS

Report

1/7

08:22 am

sabs

SAB Biotherapeutics initiated with a Buy at UBS

Medium Report

SAB Biotherapeutics initiated with a Buy at UBS

Report

1/7

02:01 am

sabs

SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.

Medium Report

SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.

Report

12/23

07:06 am

sabs

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.

Low Report

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.

Report

12/23

07:06 am

sabs

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.

Low Report

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Guggenheim to a "strong-buy" rating.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.